23 results
424B5
QLGN
Qualigen Therapeutics Inc
1 Dec 21
Prospectus supplement for primary offering
2:28pm
by other factors, including:
severity of the disease under investigation;
Qualigen’s ability to recruit clinical trial investigators of appropriate … its facilities and continue to recruit and train additional qualified personnel. Qualigen may not be able to effectively manage the expansion of its
10-KT
QLGN
Qualigen Therapeutics Inc
31 Mar 21
Annual report (with FYE transition)
4:33pm
growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit … and train additional qualified personnel. We may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
424B5
mov6bbabfv7el3x
18 Dec 20
Prospectus supplement for primary offering
1:26pm
424B5
eg1n 2xnw4
2 Oct 20
Prospectus supplement for primary offering
4:24pm
424B5
0af19uvbt jv
4 Aug 20
Prospectus supplement for primary offering
6:16am
424B5
gd6ri
10 Jul 20
Prospectus supplement for primary offering
2:35pm
424B3
eyewme7
9 Apr 20
Prospectus supplement
9:30am
S-4/A
5zf37p t0brrtthyz7
13 Mar 20
Registration of securities issued in business combination transactions (amended)
5:28pm
S-4
b1fc rj9c1n
4 Feb 20
Registration of securities issued in business combination transactions
6:26am
8-K
EX-10.2
9f75vpxnpnhkb
2 Jul 18
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
6:01am
8-K
EX-10.1
zk7k3z9nse902
7 May 18
Entry into a Material Definitive Agreement
6:03am
10-K
srno xl6cp3x0
21 Mar 16
Annual report
12:00am